ID | 1013 |
Name of the vaccine | Adacel |
Microbe | Bacteria |
Disease name | Diphtheria |
Name of bacteria | Corynebacterium diphtheriae |
Type of vaccine | Inactivated |
Nucleic acid content | DNA |
Age | 10 to 64 years |
Description of the vaccine | Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis vaccine adsorbed (Tdap vaccine). |
Name of the manufacturer | Sanofi Pasteur Limited |
Name of the manufacturing country | Canada |
Year of manufacture | 2005 |
Clinical Phase status | Approved |
Bacterial strain | Gram-positive bacillus. |
Efficacy | Based on the immune response compared to US licensed Tetanus and Diphtheria Toxoids Adsorbed For Adult Use (Td) vaccine. |
Vaccine formulation | Suspension for injection |
Dosage | Single 0.5 mL injection with first dose and wound management at 5 years, repeat vaccination at 8 years. |
Mechanism of action | Serum diphtheria antitoxin level of 1 IU/ml provides long-term protection. |
Route of administration | Intramuscular |
Indications | Active booster immunization against tetanus, diphtheria and pertussis. |
Export | Distributed by - Sanofi Pasteur Inc., USA |
Approval | US FDA |
Adjuvant | Aluminium phosphate |
Repurposing | Could be used for pertussis and tetanus. |
Side effects of vaccine | Injection site pain, myalgia, headache, malaise, body ache, tiredness, injection site swelling and erythema. |
Post vaccination | NA |
Dose type | Single dose |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NA |
Reference | https://www.fda.gov/media/119862/download |
Other name | NA |
Additional Links | https://www.rxlist.com/adacel-drug.htm#clinpharm
|